Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DR26FCYU6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,182
Award facts
- Contract value 100% obligated
- $23,181.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $23,181.96 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injectors. The award, issued on November 3, 2025, with an ultimate completion date of November 4, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capacity as a critical supplier within the federal pharmaceutical supply chain, with its established performance across numerous delivery orders spanning oncology treatments, biologics, immunosuppressants, vaccines, and specialty pharmaceuticals. The company's underlying PPV-G GEN V contract, valued at $499,999,999 with a completion date of December 31, 2036, positions it as a regional prime vendor contractor capable of fulfilling diverse and specialized pharmaceutical requirements for military medical operations globally. The delivery of Nucala, a biologic immunosuppressant agent, aligns with DMS Pharmaceutical Group's documented product portfolio and its role in supporting the Department of Defense's complex medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FCYU6?
SPE2DR26FCYU6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DR26FCYU6 worth?
The government has obligated $23,182 on SPE2DR26FCYU6.
Is contract SPE2DR26FCYU6 an order under another contract?
Yes. SPE2DR26FCYU6 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCYU6 competed?
The extent of competition for SPE2DR26FCYU6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award